Management of the adverse effects associated with intravenous bisphosphonates
Open Access
- 17 March 2006
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 17 (6), 897-907
- https://doi.org/10.1093/annonc/mdj105
Abstract
Intravenous bisphosphonates are widely used to treat hypercalcemia and to reduce skeletal-related morbidity among cancer patients. However, serious complications, generally occurring in less than 2% of patients participated in phase III clinical trials, including acute systemic inflammatory reaction, ocular inflammation, renal failure, nephrotic syndrome, electrolyte imbalance, and osteonecrosis of the maxilla and mandible have all been increasingly reported. Yet, strategies to deal with these complications are becoming clear. Acute systemic inflammatory reaction is often self-limited and becomes less intense during subsequent treatments. For patients who develop ocular symptoms, prompt ophthalmologic evaluation is crucial to determine the safety of a subsequent bisphosphonate therapy. Patients who receive long-term pamidronate should be evaluated at intervals for early sign of nephritic syndrome as timely cessation of the agent may result in a full recovery. To reduce the risk of severe electrolyte abnormalities, particularly hypocalcemia, correcting any pre-treatment electrolyte abnormality and supplementing vitamin D and calcium may be helpful. Finally, to reduce the risk of osteonecrosis of the maxilla and mandible, obtaining a full dental evaluation before treatment and avoidance of invasive dental procedures is suggested. The three commonly used intravenous bisphosphonates (pamidronate, zoledronic acid, and ibandronate), are generally safe; ibandronate has to date been the least reported to be associated with renal side effects. As clinical indications of intravenous bisphosphonates continue to expand, prescribing clinicians should be familiar with these possible adverse effects and discuss them with patients before commencing or continuing on therapy.This publication has 102 references indexed in Scilit:
- Ask Us: Some drugs affect tooth movementAmerican Journal of Orthodontics and Dentofacial Orthopedics, 2005
- Recommendations for Zoledronic Acid Treatment of Patients with Bone MetastasesThe Oncologist, 2005
- Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing RegimensThe Oncologist, 2004
- Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfectaBone, 2004
- Diplopia following intravenous administration of pamidronateEye, 2004
- Pamidronate-induced nephrotoxic tubular necrosis – a case reportClinical Nephrology, 2004
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronateSupportive Care in Cancer, 2003
- Hypocalcemia Following Pamidronate Administration for Bone Metastases of Solid Tumor: Three Clinical Case ReportsJournal of Pain and Symptom Management, 2003
- Pamidronate-Related Nephrotoxicity (Tubulointerstitial Nephritis) in a Patient with Osteolytic Bone MetastasesNephron, 2001